UnknownNot Applicable

Plasma and Lung Tissue Concentrations of Linezolid in Septic Shock Patients

46 participantsStarted 2017-10-20

Plain-language summary

The study measures the plasma and bronchoalveolar lavage fluid concentrations of linezolid in septic shock patients comparing with non-septic shock patients to confirm the impact of septic shock on PK/PD of linezolid.

Who can participate

Age range19 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. between 18 years old and 75 years old;
✓. Admitted to the ICU;
✓. Expectation, in the opinion of the investigator, that the patients' infection will require ICU stay more than 3 days;
✓. Patients diagnosed as severe pneumonia requiring mechanical ventilatory support;
✓. Severe pneumonia known or suspected to be caused by Gram-positive pathogens;
✓. Expected to treat with linezolid.

Exclusion criteria

✕. Unable to take bronchoalveolar lavage via bronchofiberscopy;
✕. Allergy, hypersensitivity or a serious reaction to linezolid;
✕. Treatment with linezolid during the previous 72 hours;
✕. Pregnancy.

What they're measuring

The plasma and bronchoalveolar lavage fluid concentrations of linezolid

Timeframe: Baseline, Day 3, Day 7

Trial details

NCT IDNCT03308227

SponsorSoutheast University, China

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-02-28

Contact for this trial

Haibo Qiu, PHD

8602583262550 haiboq2000@163.com

View on ClinicalTrials.gov More Septic Shock trials